When you search for ‘ceftidoren’ on Wikipedia, you will get a surprise: there is no entry. However, a search on the web tells us that Spectracef (ceftidoren pivoxil) still exists. Gee, now the drug is spelled ‘cefditoren’ and – looking
Continue reading Choose your Outcome: How Design Minutiae Affect Trial Results → Like this: Like Loading...
Posted in QIDP Antibiotics, The News, The Viewpoint |
Tagged AECB, antibiotic blog, Avelox, Cefditoren, cefuroxime, control group, cross-study design differences, FDA review, Harald Reinhart, historical comparison studies, impact of evaluation criteria, impact of selection criteria, LAIV, Levaquin, levofloxacin, medical officer, meta-analysis, moxifloxacin, QIDP, RCT, Spectracef, study design |
Very recently we came across several studies in which small differences in design had a major impact on outcomes. A blog is not a good place to dig deeply into the minutiae of study design as the discussion becomes quickly very dry and quite technical. However, readers
Continue reading Is LAIV Dead or Just on LAIV-Support? → Like this: Like Loading...
Posted in Recent Literature, The News |
Tagged ACIP, Advisory Committee on Immunization Practices, antibiotic blog, AstraZeneca, CDC, effectiveness vs efficacy, Finland, FluMist, Harald Reinhart, IIV, influenza vaccine, injectable influenza vaccine, LAIV, MedImmune, P. aeruginosa. S. aureus, randomized controlled trial, RCT, RSV, Test Negative design, TIV, TND, vaccine effectiveness, vaccine efficacy, VE |